Shenzhen Ninenovo Technology Limited appears in FDA device records as the applicant for a single 510(k) submission, K260490, for the Ninenovo Blood Oxygen Ring. The filing covers nine model identifiers, BORMB-01-6 through BORMB-01-14, and received a substantially equivalent decision dated October 2, 2026. The record places the device in the oximeter classification, product code DQA, regulation 21 CFR 870.2700, with a Cardiovascular review panel and Class II designation. A press release issued by Ninenovo identifies Shenzhen Ninenovo Technology Limited as the parent company of RingConn and links the clearance to its Smart Ring. [1][2][7][9]
The cleared device and its stated use
The Ninenovo Blood Oxygen Ring is described in its user manual as a wireless, non-invasive, stand-alone pulse oximeter intended for spot-check or continuous data collection of oxygen saturation of arterial hemoglobin and pulse rate through the index finger in adult patients. The manual states use in hospitals and home environments for up to twelve hours in non-motion and well perfused conditions, and states the device is not intended for single-use or out-of-hospital transport use and does not have alarms. [6]
The FDA record lists the device as prescription rather than over-the-counter, and the submission comparison in the review document places the subject device alongside a primary predicate, K221361, and a reference device, K191088, all sharing product code DQA and prescription status. [2][7]
Filing history and review path
K260490 was received on February 13, 2026, and decided on October 2, 2026, as a Traditional 510(k) with a Summary statement and no third-party review. The applicant contact on the FDA record is Guoxing Wang, with a Shenzhen address in the Nanshan District. The review correspondence is directed to Wilson Peng, RA Manager at Shenzhen Bosstar Consulting Company Limited, in Shenzhen's Bao'An District. [1][2][7]
The decision appears in the FDA list of 510(k) final decisions rendered since October 1, 2026, published October 2, 2026, where the device is recorded as substantially equivalent. The same decision date and outcome appear in third-party indexes of the filing. [4][5][8]
Corporate identity and brand relationship
A press release distributed by Ninenovo on October 10, 2026, states that Shenzhen Ninenovo Technology Limited is the parent company of RingConn and that its Smart Ring received 510(k) clearance for non-invasive blood oxygen measurement under clearance number K260490. That parent-and-brand relationship is asserted by the publisher; the FDA filing itself names only Shenzhen Ninenovo Technology Limited as applicant. [9][1]
The FDA record carries a Shenzhen city and postal code from the applicant's filing address, and the review letter uses a separate Shenzhen consulting address. Neither address is documented as a corporate headquarters. No website, customer list, or commercial availability information appears in the linked FDA records. [1][2]
What the record does and does not establish
The supplied collection contains one linked 510(k) record, K260490, with one substantially equivalent decision, and the smaller record sample likewise contains that single entry. These counts describe the supplied filings as of the snapshot date and are not measures of total company sales, total portfolio, or safety performance. No recall records appear in the public information. [1][4]
The user manual includes an FCC radio-frequency exposure statement requiring that the transmitter not be co-located or operated with any other antenna or transmitter. Beyond the intended-use language and the regulatory classification, the public documents do not document clinical performance results, measurement accuracy figures, or independent testing. [6][8]
